DHR - Danaher Corporation
NYSE
->
Healthcare
->
Diagnostics & Research
Washington,
United States
Type: Equity
DHR price evolution
DHR
| (in millions $) | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7031 | $5864 | $12277 | $8575 |
| Short term investments | ||||
| Net receivables | $3379 | $3922 | $4201 | $4199 |
| Inventory | $2645 | $2594 | $3024 | $3183 |
| Total current assets | $14372 | $13937 | $21205 | $17461 |
| Long term investments | ||||
| Property, plant & equipment | $4562 | $4553 | $4302 | $4176 |
| Goodwill & intangible assets | $60734 | $62354 | $57941 | $58893 |
| Total noncurrent assets | $69030 | $70551 | $66529 | $67441 |
| Total investments | ||||
| Total assets | $83402 | $84488 | $87734 | $84902 |
| Current liabilities | ||||
| Accounts payable | $1679 | $1766 | $1894 | $1956 |
| Deferred revenue | ||||
| Short long term debt | $1746 | $1695 | $2547 | $1590 |
| Total current liabilities | $7778 | $8274 | $9367 | $8404 |
| Long term debt | $16417 | $16707 | $19513 | $18285 |
| Total noncurrent liabilities | $22177 | $22724 | $25952 | $24774 |
| Total debt | $18163 | $18402 | $22060 | $19875 |
| Total liabilities | $29955 | $31002 | $35319 | $33178 |
| Shareholders' equity | ||||
| Retained earnings | $41962 | $41074 | $42272 | $41344 |
| Other shareholder equity | -$2744 | -$1748 | -$3959 | -$3576 |
| Total shareholder equity | $53442 | $53486 | $52407 | $51716 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5864 | $5995 | $2586 | $6035 |
| Short term investments | ||||
| Net receivables | $3922 | $4918 | $4631 | $4045 |
| Inventory | $2594 | $3110 | $2767 | $2292 |
| Total current assets | $13937 | $15883 | $11648 | $13802 |
| Long term investments | $27 | |||
| Property, plant & equipment | $4553 | $3956 | $3790 | $3262 |
| Goodwill & intangible assets | $62354 | $60052 | $64027 | $56702 |
| Total noncurrent assets | $70551 | $68467 | $71536 | $62359 |
| Total investments | ||||
| Total assets | $84488 | $84350 | $83184 | $76161 |
| Current liabilities | ||||
| Accounts payable | $1766 | $2296 | $2569 | $2049 |
| Deferred revenue | ||||
| Short long term debt | $1695 | $591 | $8 | $11 |
| Total current liabilities | $8274 | $8389 | $8140 | $7402 |
| Long term debt | $16707 | $19086 | $22168 | $21193 |
| Total noncurrent liabilities | $22724 | $25871 | $29867 | $28982 |
| Total debt | $18402 | $19677 | $22176 | $21204 |
| Total liabilities | $31002 | $34268 | $38007 | $36384 |
| Shareholders' equity | ||||
| Retained earnings | $41074 | $39205 | $32827 | $27159 |
| Other shareholder equity | -$1748 | -$2872 | -$1027 | -$368 |
| Total shareholder equity | $53486 | $50082 | $45167 | $39766 |
| (in millions $) | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $5796 | $6405 | $6873 | $7157 |
| Cost of revenue | $2309 | $2873 | $3116 | |
| Gross Profit | $3487 | $3779 | $4000 | $4041 |
| Operating activities | ||||
| Research & development | $368 | $417 | $418 | |
| Selling, general & administrative | $1807 | $2145 | $2194 | |
| Total operating expenses | $2175 | $2442 | $2562 | $2612 |
| Operating income | $1312 | $1438 | $1429 | |
| Income from continuing operations | ||||
| EBIT | $1336 | $1470 | $1459 | |
| Income tax expense | $183 | $111 | $268 | $286 |
| Interest expense | $65 | $32 | $73 | $67 |
| Net income | ||||
| Net income | $1088 | $1079 | $1129 | $1106 |
| Income (for common shares) | $1088 | $1129 | $1106 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $23890 | $31471 | $22284 | |
| Cost of revenue | $12522 | $9809 | ||
| Gross Profit | $14034 | $18949 | $12475 | |
| Operating activities | ||||
| Research & development | $1745 | $1348 | ||
| Selling, general & administrative | $8516 | $6896 | ||
| Total operating expenses | $8832 | $10261 | $8244 | |
| Operating income | $8688 | $4231 | ||
| Income from continuing operations | ||||
| EBIT | $8503 | $4770 | ||
| Income tax expense | $823 | $1083 | $849 | |
| Interest expense | $17 | $211 | $275 | |
| Net income | ||||
| Net income | $4743 | $7209 | $3646 | |
| Income (for common shares) | $7103 | $3510 | ||
| (in millions $) | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Net income | $1088 | $1129 | $1106 | |
| Operating activities | ||||
| Depreciation | $586 | $554 | $562 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $60 | $92 | $109 | |
| Total cash flows from operations | $1739 | $1672 | $1926 | |
| Investing activities | ||||
| Capital expenditures | -$291 | -$361 | -$337 | |
| Investments | -$44 | $21 | -$98 | |
| Total cash flows from investing | -$321 | -$7081 | -$329 | -$431 |
| Financing activities | ||||
| Dividends paid | -$177 | -$821 | -$199 | -$218 |
| Sale and purchase of stock | -$1 | $55 | $30 | |
| Net borrowings | $68 | $2603 | -$3 | |
| Total cash flows from financing | -$133 | -$273 | $2443 | -$208 |
| Effect of exchange rate | -$118 | $59 | -$84 | -$91 |
| Change in cash and equivalents | $1167 | -$131 | $3702 | $1196 |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $7209 | $6433 | $3646 | |
| Operating activities | ||||
| Depreciation | $2222 | $2168 | $1775 | |
| Business acquisitions & disposals | -$637 | -$10935 | -$20145 | |
| Stock-based compensation | $336 | $218 | $187 | |
| Total cash flows from operations | $8519 | $8358 | $6208 | |
| Investing activities | ||||
| Capital expenditures | -$1143 | -$1281 | -$789 | |
| Investments | -$505 | -$808 | -$329 | |
| Total cash flows from investing | -$7081 | -$2234 | -$12987 | -$21239 |
| Financing activities | ||||
| Dividends paid | -$821 | -$818 | -$742 | -$615 |
| Sale and purchase of stock | $31 | $86 | $1882 | |
| Net borrowings | -$1688 | $1967 | -$1926 | |
| Total cash flows from financing | -$273 | -$2570 | $1295 | $1006 |
| Effect of exchange rate | $59 | -$306 | -$115 | $148 |
| Change in cash and equivalents | -$131 | $3409 | -$3449 | -$13877 |
News
|
AdaptHealth Corp. (NASDAQ:AHCO) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance
8 May 2024
|
|
25 Richest Billionaires in Manufacturing Industry
Insider Monkey via Yahoo Finance
6 May 2024
|
|
Markel (MKL) Q1 Earnings, Revenues Miss Estimates, Rise Y/Y
Zacks via Yahoo Finance
3 May 2024
|
|
Envista Holdings Corporation (NYSE:NVST) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance
2 May 2024
|
|
Corporate insiders are on a buyers’ strike — a sign of more downward pressure on stocks
Market Watch
2 May 2024
|
|
The Forgotten Stock Advice That Delivers 170%+ Payout Growth
Forbes
1 May 2024
|
|
3 BNY Mellon Mutual Funds for Reliable Returns
Zacks via Yahoo Finance
29 Apr 2024
|
|
What Should You Do With Danaher Stock At $250 After Q1 Beat?
Forbes
26 Apr 2024
|
|
BofA raises Danaher stock target on bioprocessing market signs By Investing.com
Investing.com
26 Apr 2024
|
|
Danaher CEO Blair Rainer sells over $11m in company stock By Investing.com
Investing.com
25 Apr 2024
|
Fundamentals
| Market cap | $187.65B |
|---|---|
| Enterprise value | $198.79B |
| Shares outstanding | 740.60M |
| Revenue | $26.23B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $4.40B |
| Revenue Q/Q | -19.13% |
| Revenue Y/Y | -15.25% |
| P/E ratio | 42.63 |
|---|---|
| EV/Sales | 7.58 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 7.15 |
| P/B ratio | 3.34 |
| Book/Share | 75.87 |
| Cash/Share | 9.49 |
| EPS | $5.94 |
|---|---|
| ROA | 5.17% |
| ROE | 8.34% |
| Debt/Equity | 0.58 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.85 |
| Quick ratio | 1.51 |